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ABSTRACT
&RORUHFWDO FDQFHU LV RQH RI WKH PRVW FRPPRQ FDQFHU ZRUOGZLGH 7KH LQFLGHQFH DQG PRUWDOLW\ WUHQG LQ 
GLIIHUHQW DUHDV RI WKH ZRUOG YDULHV &RORUHFWDO FDQFHU LQFLGHQFH DQG PRUWDOLW\ DUH LQFUHDVLQJ LQ VRPH FRXQWULHV 
7KHUH DUH DOVR HSLGHPLRORJLFDO VKLIW WRZDUGV \RXQJHU DJH EHORZ  0RVW FRPPRQ QRQLQYDVLYH VFUHHQLQJ 
WHVWV DUH IHFDO LPPXQRFKHPLVWU\ WHVW ),7 DQG IHFDO RFFXOW EORRG WHVW )2%7 %RWK KDYH JRRG VHQVLWLYLW\ 7KH 
EHVW LQYDVLYH PHWKRG IRU FRORUHFWDO VFUHHQLQJ LV VWLOO FRORQRVFRS\ +HUHGLWDU\ FRORUHFWDO FDQFHU LV DQ LPSRUWDQW 
IDFWRU LQ \RXQJHU DJH FRORUHFWDO FDQFHU )DPLOLDO DGHQRPDWRXV SRO\SRVLV DQG /\QFK V\QGURPH DUH PRVW FRPPRQ 
KHUHGLWDU\ &5& ,Q IDPLOLDO RU KHUHGLWDU\ &5& WKH FKDQFH RI GHYHORSLQJ WKH FDQFHURXV IRUP RI WKH GLVHDVH LV 
QHDUO\ LQHYLWDEOH *HQHWLF WHVWLQJ PD\ EHQH¿W WKH SDWLHQWV DQG WKHLU IXWXUH SURJHQLHV
Keywords: FRORUHFWDO FDQFHU KHUHGLWDU\ FRORUHFWDO FDQFHU O\QFK V\QGURPH IDPLOLDO DGHQRPDWRXV SRO\SRVLV
ABSTRAK
Kanker kolorektal adalah salah satu kanker yang paling banyak ditemukan. Tren insidens dan mortalitas 
berbeda-beda di berbagai negara. Pada beberapa negara didapatkan peningkatan insidens kanker kolorektal. 
Terdapat pergeseran insidens ke usia yang lebih muda. Pemeriksaan skrining yang paling umum adalah IeFal 
immunoFhemistry test ),T dan IeFal oFFult blood test )2%T dimana keduanya memiliki sensiti¿tas yang 
baik. Metode invasif yang paling baik saat ini masih kolonoskopi. Kanker kolorektal yang bersifat herediter 
merupakan salah satu faktor yang penting pada kanker di usia muda. )amilial adenomatous polyposis )$P 
dan /ynFh syndrome merupakan sindrom yang sering dikaitkan dengan kanker kolorektal yang herediter. Pada 
pasien-pasien dengan )$P dan /ynFh syndrome risiko terMadinya kanker kolorektal tidak dapat dihindarkan. 
 
Kata kunci: kanker kolorektal kanker kolorektal herediter lynFh syndrome familial adenomatous polyposis
INTRODUCTION
Colorectal cancer (CRC) or bowel cancer is a 
malignancy condition in the colon and/or rectum.1 Its 
incidence and mortality are increasing progressively in 
general population. However, this trend is also followed 
by incidence in younger age cohorts.2,3 Furthermore, 
there is a shift of CRC incidence proportion from 
Western part of the world to Asian countries.
 This new changes are associated with adoption of 
Western lifestyles and diets.4 There are sporadic and 
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hereditary CRC, albeit hereditary CRC may occur 
sporadically as well in small numbers. 
The risk for developing neoplasia is very high in 
patient with hereditary CRC. Although hereditary CRC 
clinically can be distinguished, genetic testing may 
EHQH¿WIRUWKHSDWLHQWDQGWKHLUIDPLO\7KLVUHYLHZ
will discuss upon these changes and early detection of 
the disease in the population.
Epidemiology of Colorectal Cancer
Colorectal cancer (CRC) is one of the most common 
cancer worldwide, infesting as much as 9.7% of all 
new cancer cases.1,5 It ranks third in men and second in 
female with worldwide incidence of 746,000 cases and 
614,000 cases, respectively, and fourth in cancer deaths 
(8%).1,6 In 2016, data from the United States (US) 
showed that there were total incidences of 134,490 
cases from 70,820 men and 63,670 women with total 
deaths due to CRC as many as 49,190 cases; 26,020 
in men and 23,170 in women.6 In Asia, the highest 
incidence is found in the Eastern part of the continent 
with incidence of 421,250.4 
The incidence and mortality trend in different 
areas of the world varies. In countries with medium 
to high human development index (HDI), such as East 
European countries, Asian countries, and countries in 
South America, the incidence and death rates of CRC 
have increased promptly.5 In the contrary, countries 
with very high HDI (US, Australia, New Zealand, 
and Western European Countries) have stabile or even 
waning incidence and mortality cases due to early 
detection and management through polypectomy.5 
Based on the 2012 GLOBOCAN data of CRC 
incidence and mortality trends, Arnold M et al.5 classify 
FRXQWULHVLQWRWKUHHJURXSV7KH¿UVWJURXSFRQVLVWVRI
countries with inclining or stable propensity in CRC 
incidence and mortality (Philippines, China, Russia, 
Spain, Brazil, Croatia) and the second group comprises 
of countries with increasing incidence but decreasing 
mortality trend (Singapore, Canada, Denmark, Swiss, 
Italy, Sweden). The countries that belong to the third 
group underwent declining rates of incidence and 
mortality for the past 10 years (US, Australia, New 
Zealand, France, Japan, Israel). Decreasing mortality 
WUHQGLQWKHODWWHUWZRJURXSVUHÀHFWVDQLQFUHPHQWRI
survival rates of CRC patients and is suspected to have 
association with good management programs. On the 
RWKHUKDQG%UD]LOZKLFKLVLQFOXGHGLQWKH¿UVWJURXS
has experienced emerging deaths in men and women 
due to CRC for the last 30 years. 
Recent Predilection of Colorectal Cancer in 
Younger Cohorts
Nowadays, there are shifting trends of CRC 
incidence. Colorectal cancer is a disease renowned in 
developed countries such as in the US and Western 
European countries, occupying around 60% of all CRC 
cases.2 However, there has been a drop of incidences 
from 2002 to 2008 as much as 6% in these regions for 
the past decades, and instead is followed by two- to 
four- fold increase of new cases in Asian countries.7 In 
China, for instance, the incidence rates of colon cancer 
between 1972 and 2005 had increased nearly three 
folds, whilst the increment of rectal cancer incidences 
was not as high. 
Another changing trend is the declining incidence of 
CRC in patients aged 50 years and older accompanied 
by increasing novel cases in younger patients in 
Western countries.3,8 Data from the US from the 
Surveillance, Epidemiology, and End Results (SEER) 
database revealed that the annual incidence rate for all 
three types of colorectal cancers; localized (to the colon 
and rectum), regional (spread to neighboring structure 
or organ) and distant (metastases to distal area) disease; 
steadily decreased over the past 35 years in patients 
older than 50 years with the population over 75 years 
having the steepest decline.3,8 In contrast, increment 
of CRC cases were observed in younger cohort aged 
20-34 years.3,8 Rectal cancer incidence in western 
population patients below 40 years had increase four 
times for the past 30 years.3 
In general, there are many hypotheses to explain 
these shifting trends; improvements of management 
programs in developed countries and screening 
programs in developing countries, behavioral changes 
due to constant economical changes in developing 
countries, including arising incidence of obesity, 
physical inactivity, along with adoption of Western 
diets (cholesterol-rich diets from red and processed 
meat consumption) and lifestyles (e.g. alcohol 
consumption and habitual smoking) were found to 
link with colorectal cancer.3,4,6 However, other regional 
etiologies may remain; carcinogenic chemicals 
contained inside the drinking water in China and 
Taiwan has been associated with the increment of rectal 
cancer incidence and mortality.3 Others also predicted 
the predilection of this disease towards vulnerable 
ethnicities.7 
Screening Tests for Colorectal Cancer
Some countries such as the US, Israel, and Japan 
have managed to reduce CRC incidence and mortality.5 
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Those countries were known to apply national screening 
programs for CRC since 1990.9 Screening programs 
may initially contribute to the escalating number of 
incidence epidemiologically.5 However, the number 
will drop in the long run if prompt management is done 
after the early diagnosis.56RPHVSHFL¿FVFUHHQLQJWHVWV
include fecal immunochemistry test (FIT), fecal occult 
EORRGWHVW)2%7ÀH[LEOHVLJPRLGRVFRS\FRPSXWHG
tomography (CT) colonography, and colonoscopy. 
7KH¿UVWWZRPHWKRGVDUHWKHFRPPRQHVWPHWKRGWR
be used for screening programs worldwide and are not 
invasive, whilst the latter three are.9 
One time FIT procedure has sensitivity of 60-85% 
and 20-50% to detect colorectal cancer and advanced 
adenoma, respectively.10,11 It also has a pooled 
VSHFL¿FLW\RIDFFRUGLQJWRTXDOL¿HGVWXGLHV12 It 
detects the presence of hemoglobin in the feces without 
requiring any dietary restrictions beforehand. In 
addition, when being combined with DNA marker test 
(FIT-fecal DNA test), the sensitivity to detect CRC and 
adenomas with high-grade dysplasia rise to 92% and 
69%.10<HWLWVVSHFL¿FLW\GURSVWR12 Another 
non-invasive test is FOBT, which is less expensive than 
FIT to date.12 The test, traditionally called guaiac FOBT 
(gFOBT), detects peroxidase activity of heme element 
in the blood hence could detect very mild blood loss 
from the gastrointestinal (GI) tract.12 The sensitivity 
of this test to detect CRC and advanced adenoma is 
50-75% and 20-25%, respectively.10 Moreover, annual 
screening in US population using gFOBT had reduced 
mortality rate by 33%.13 However, the test is not 
VSHFL¿FIRUKXPDQEORRGDQGVXVFHSWLEOHWRUHGXFLQJ
agent such as vitamin C.10 
Flexible sigmoidoscopy has a sensitivity above 
95% for detecting CRC in the distal colon and 70% for 
detecting advanced adenoma.10 Whilst the utilization 
of flexible sigmoidoscopy can reduce incidence 
and mortality by approximately 20-30%, albeit this 
QXPEHULVQRWVLJQL¿FDQWDQGWKHWRROKDVORZHUUDWH
in detecting proximal colon adenomas.10,11,13 Likewise, 
the absence of sedation during the procedure may 
lead to an unhappy experience for the patients.11 The 
CT colonography has sensitivity higher than 90% for 
detecting CRC and advanced adenoma more than 1 
cm in size.10 Yet, lesions below 10 mm and not using 
laxative would reduce its sensitivity, making it less 
than colonoscopy, hence lesions above 6 mm in size 
VHQVLWLYLW\RIDQGVSHFL¿FLW\RIVKRXOGEH
IXUWKHU FRQ¿UPHGZLWK FRORQRVFRS\10 Colonoscopy 
has the highest sensitivity for the detection of cancer 
and precancerous lesions hence becomes the gold 
standard for every screening program. It allows biopsy 
and removal of any adenoma. It is proven to be 53-72% 
and 31% effective on reducing CRC incidence and 
mortality, respectively.10-12 However, this procedure 
is highly operator-dependent and requires substantial 
amount of preparation for bowel cleansing.
Screening Programs of Colorectal Cancer
Colorectal cancer has prominent features, which 
allow screening to be highly beneficial; frequent 
incidences, chronic preclinical phase, treatable 
precursor, association of mortality rate with disease 
stages and expensive cancer treatment.9 Two 
approaches to screening include programmatic/
organized screening and opportunistic screening.9,11 
Screening offers, improved quality monitoring, and 
systematic follow-ups are the prominent features of 
the programmatic screening.9,11 
The International Agency for Research on 
Cancer (IARC) has mentioned some important 
characteristics for an organized screening program in 
the 2010 European Guidelines for Quality Assurance 
in Colorectal Cancer Screening and Diagnosis.9 The 
organized screening itself requires follow-up of the 
positively-screened patients and the target participants 
for the population should be minimum 65%.9 Some 
countries had conducted organized national screening 
programs before, including Ireland, Denmark, France, 
Italy, Netherlands, Norway, Poland, Spain, Sweden, 
and United Kingdom (UK) in the European region; 
Chile, Brazil and Argentina in the South America; 
Hongkong, Israel, Japan, South Korea, Thailand and 
Singapore in Asia.9 
Contrastly, opportunistic screening have 3 different 
approaches; multiple options which allows the patient 
to choose 2 or more options after being informed of 
WKH EHQH¿W ULVN DQG FRVW RI HDFK VHTXHQWLDOZKHUH
the patients will only be given other options if they 
decline the American College of Gastroenterology- 
and American Society Gastrointestinal Endoscopy-
SUHIHUUHG RSWLRQ FRORQRVFRS\ DQG ULVN VWUDWL¿HG
which merely allows the high risk patients to undergo 
colonoscopy and and the low risk ones to undergo 
other tests.11 Most American guidelines recommend 
screening annually using gFOBT and/or FIT and every 
10 years using colonoscopy.11 
Epidemiology of Hereditary Colorectal Cancer
Colorectal cancer can occur due to many factors. 
Approximately 15-30% of CRCs has a familial 
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component and around 2-5% to 1/3 of all CRCs 
(depends on the population) are hereditary with a 
highly penetrant gene mutation.14 Recently, there is 
rising evidence of CRC occurrences in adolescence 
and young adults.2 As aforementioned, according to 
the SEER database and the World Health Organization 
(WHO) database from the US and European Union 
(EU), respectively, CRC incidence from 1992 to 2005 
in younger cohorts aged 20-29 years has increased in 
men and women.2 Interestingly, the majority of the 
cases have predilection on the distal colon and the 
rectum and mostly are poorly differentiated or have 
mucinous type hence they are considered aggressive. 
However, the rate of 5-year prognosis is either similar 
or slightly higher than in older patients.2 Approximately 
1 in 180 early onset CRC patients is considered as 
hereditary colorectal cancer patient, albeit it is evident 
that many familial cases were not always reported.2 
As a result, studies concluded that the frequency of 
familial cases ranges from 3-20% of all CRC cases.2 
 Familial adenomatous polyposis, except for 
MAP, is an autosomal dominant disorder.14,15,16 The 
classic, profuse and attenuated types of FAP are caused 
by mutation in the adenomatous polyposis coli (APC) 
gene on chromosome 5, which is a tumor suppressor 
gene, whilst the other types such as MUTYH-associated 
polyposis (MAP), Juvenile polyposis syndrome (JPS), 
Peutz-Jeghers syndrome (PJS), Cowden syndrome, 
and serrated polyposis syndrome are caused by 
mutation in other genes.14,15,16 Lynch syndrome is also 
inherited in an autosomal dominant manner and, as 
aforementioned, is mostly caused by disruption of the 
MMR system in the DNA (76.4%) due to mutations 
of MMR genes, such as MLH1, MSH2, MSH6, PMS2 
and EPCAM.17,18,19 
As a result, there will be numerous inconsistent 
size of microsatellite nucleotide in the gene, termed 
microsatellite instability (MSI). Both FAP and LS 
have extra-colonic malignancy. Lynch syndrome 
patients may come to the hospital with cancers in 
the endometrial, ovaries, upper urinary tract, small 
intestine, stomach, biliary tract, larynx and even 
the brain.17,18,19 Likewise, FAP patients may present 
clinical conditions such as congenital hypertrophy of 
the retinal pigment epithelium (CHRPE), osteomas, 
dental abnormalities, desmoid tumors, adrenal masses, 
hepatoblastoma, pancreatic cancer, medulloblastoma 
and papillary thyroid carcinoma, albeit the latter is 
suggestively caused by hormonal or environmental 
factors.15,16 
Familial Adenomatous Polyposis
Familial adenomatous polyposis was said to affect 
1 in approximately 7,000-29,000 people and accounts 
for less than 1% of all CRCs.16 Without any family 
history, spontaneous cases could occur in 10-30% all 
FAP patients, albeit there are some reports claiming that 
de novo APC mutation rate is 25-30%.16 One example 
from a study by Mork et al showed that approximately 
12 out of 39 patients (30.77%) below 35 years who 
are diagnosed with FAP, AFAP and LS have de novo 
mutations.20 However, studies have found that 10-
15% of de novo mutations may result from somatic 
mosaicism.15 All FAP patients will have CRC if not 
treated and 95% have progressed to malignant stage by 
the age of 50.15 Multiple adenomas (may reach more 
WKDQRQWKHFRORQRUUHFWXPDVLWV¿UVWLQYHVWPHQW
are mostly found by the age of 35 years.14,15 Duodenal 
adenomas and adenocarcinomas may also arise in 50-
90% and 1-10% FAP patients, respectively, mostly 
in patients aged around 75 years.15 The occurrences 
of extraintestinal manifestations of FAP including 
CHRPE, epidermoid cysts, osteomas, desmoid 
tumours, supernumerary teeth, adrenal adenoma are 
70-90%, 50%, 50-90%, 10-30%, 70-80% and 7-13% of 
all FAP cases, respectively.15 Pancreatic, thyroid, liver 
and central nervous system (usually medulloblastoma) 
malignancy is approximately 2%, 1-2%, 1-2% (1 
KHSDWREODVWRPDFDVHVLQ)$3SDWLHQWVDQG
respectively.15 
Lynch Syndrome
Lynch syndrome affects 1-4% of all newly 
diagnosed CRCs and 2% of all endometrial cancers.18 
However, the prevalence rate in patients without 
any family history is around 3.5-6.4% of all LS.19 
Manifestation of this disease in the colon is the 
commonest; 63%, followed by endometrium (9%) 
and urinary tract (5-6%).18 Approximately, 70-90% of 
this disease is shown with MSI. In general population, 
the carrier frequency of MMR genes mutations is 
predicted to be 0.051% for MLH1 mutations, 0.035% 
for MSH2 mutations, 0.132% for MSH6 mutations and 
0.140% for PMS2 mutations, albeit the latter two were 
factually being uncommon.19 These predictions were 
made by a model constructed from 5744 patients with 
&5&DQG¿UVWGHJUHHUHODWLYHVLQ86&DQDGD
and Australia who are listed in Colon Cancer Family 
Registry (CCFR).19 The prevalence of the disease itself 
is different between populations.
 Due to founder mutations effect, the mutated genes 
in most cases likewise vary between countries. The 
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frequency of mutations in MLH1 and MSH2 genes in 
Asian, American, and European populations is 15.44%, 
20.43% and 15.43%, respectively.21 In Iceland, Lynch 
syndrome has affected 0.442% of its population with 
highest number of patients having MSH6 and PMS2 
mutations, whilst founder mutations in MSH2 and 
MSH6 genes are regarded to be the most common in 
Ashkenazi Jewish ancestry.19 
Risk of Developing Neoplasia in Hereditary 
Colorectal Cancer Patients
Independen t ly,  f ami ly  h i s to ry  remains 
tremendously devastating as a risk factor for colorectal 
cancer. In people with familial or hereditary CRC, 
the chance of developing the cancerous form of the 
disease is nearly inevitable. The cumulative lifetime 
risk of Lynch syndrome (in MMR mutation carriers), 
FAP, AFAP, MAP, Juvenile polyposis, Peutz-Jeghers 
syndrome, Cowden syndrome, and serrated polyposis 
syndrome is 50-80%, 100%, 69%, 43-100%, 38-68%, 
39%, 9-16%, and 50%, respectively, albeit the latter 
is rarely inherited. The lifetime risks of CRC in LS 
SDWLHQWVZLWKFRQ¿UPHGPXWDWLRQRI0/+06+
MSH6, and PMS2 are 22-74%, 10-70%, and 15-20%, 
respectively. 
Besides the existence of the mutating gene, 
hereditary CRC also tends to occur in earlier age. The 
average age of sporadic and hereditary CRC patients 
is 69 and 38-66 years. In the American Clinical 
Guideline (ACG), it is mentioned that information 
regarding family history of cancer or premalignant 
stage in the GI should be obtained.22 Any presence of 
SRO\SVLQ¿UVWSDUHQWVFKLOGUHQVLEOLQJRUVHFRQG
degree (grandparents, nieces/nephews, aunts/uncles, 
grandchildren, and half siblings) relatives should 
likewise be explored.14,22 Screening for population at 
ULVNDQGZLWKFRQ¿UPHG/6FDUULHUFRQGLWLRQVKRXOG
be done every 2 years starting from the age of 20-25 
years and annually, respectively, by using colonoscopy.
(14) These patients are also recommended for 
endometrial or ovarian cancer and gastric or duodenal 
cancer starting the age of 30-35 years by endometrial 
biopsy or transvaginal ultrasound (TVUS) and 
esophageal duodenoscopy (EGD) and gastric biopsy, 
respectively.14 In patients diagnosed or having family 
history of FAP/MAP/AFAP, annual colonoscopy or 
ÀH[LEOH VLJPRLGRVFRS\ VKRXOG EH SHUIRUPHG VLQFH
puberty.14 
Risk of Developing Neoplasia in First-degree 
Relatives
There is no current guideline to determine the 
amount of information needed from history taking 
to diagnose a hereditary colorectal cancer case. Still, 
IRFXVLQJWKHGDWDRQ&5&FDVHVLQ¿UVWVHFRQGDQG
third- degree relatives and the age of the relatives 
ZKHQEHLQJ¿UVWGLDJQRVHGWRKDYH&5&FRXOGEHD
good start. Separately collecting data from maternal 
and paternal lineage can be done as a next step. Self-
UHSRUWLQJFDQFHUFDVHVLQ¿UVWGHJUHHUHODWLYHV)'5V
and more distant relatives has the accuracy of >75% 
and 50-80%, respectively.14 
A 6 years cross sectional study by Quintero et al in 
Spain showed that out of 8,500 people, patients with 
)'5VKDYHDVLJQL¿FDQWO\KLJKHUULVNIRUGHYHORSLQJ
advanced adenoma, multiple non-advanced adenomas 
and advanced neoplasia in comparison to the average-
risk individuals who in the study are patients between 
the age of 50 and 69 years with no family history 
of CRCs.23 Albeit patients with 1 FDR do not have 
DQ\VLJQL¿FDQWGLIIHUHQFHLQULVNRIGHYHORSLQJ&5&
UHJDUGLQJRIDQ\DJHZKHQ¿UVWO\GLDJQRVHG$QRWKHU
study by Chau et al.24 calculated the epidemiological 
risk of familial CRCs by using complicated calculation 
that inputs factors associated with closer genetic 
UHODWLRQVKLSVXFKDV¿UVWVHFRQGDQGWKLUGGHJUHH
kinships into a formula termed familial aggregation 
index. The data was acquired from 10,066 families 
using the Colon Cancer Family Registry in the US, 
Australia, and Canada for 10 years. It suggests that a 
group of families with the highest familial aggregation 
index also have higher risk for developing CRCs 
(standardized index ratio of 7.11, 95% CI). Although 
familial aggregation index is seemed to be associated 
with standardized index ratio, the study did not provide 
any data regarding their correlation. 
Genetic Testing in Hereditary Colorectal Cancer
In the clinical setting, CRC in the family from 
history taking and unusual appearance of the polyp 
PD\LQGLFDWHKHUHGLWDU\&5&+RZHYHUFRQ¿UPDWLRQ
IURPJHQHWLFWHVWLQJPD\EHQH¿WWKHSDWLHQWVDQGWKHLU
future progenies. In the clinical setting, suspicion of 
SDWLHQWVZLWK/6VKRXOGEHFRQ¿UPHGXVLQJ$PVWHUGDP
criteria, Revised Bethesda guidelines, and colorectal 
cancer risk assessment tool.22,25 These patients should 
be tested genetically. As aforementioned, MSI is 
detected in LS cases due to defective genes associated 
with DNA mismatch repair, such as MLH1, MSH2, 
MSH6, PMS2 and EPCAM genes. Mutation of 
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these genes is detectable through MSI testing and 
immunohistochemical (IHC) analysis, the latter detects 
the protein products of the genes.19,25 Both tests are 
cost-effective and their results are correlated one 
another.19,22,25 The sensitivity of MSI testing for MLH1 
and MSH2 along with MSH6 and PMS2 mutations are 
DQGUHVSHFWLYHO\DQGWKHVSHFL¿FLW\
of this test is 90%. 
7KH VHQVLWLYLW\ DQG VSHFL¿FLW\ RI ,+& WHVWLQJ LV
83% and 89%, respectively.22 Patients with loss of 
expression in MLH1 should be further assessed for 
BRAF V600E mutation or analysed for methylation 
in the MLH1 promoter to rule out sporadic cases.22,25 
6XVSLFLRQ WRZDUGV)$3 ULVHV IURP VSHFL¿F FOLQLFDO
¿QGLQJV VXFK DV ! FRORUHFWDO DGHQRPDV IDPLO\
history, and extra colonic manifestations. Syngal et 
al recommend doing genetic sequencing for APC 
and MUTYH gene mutations in patients suspected 
adenomatous polyposis syndromes.22 It predicts the 
patient’s phenotype but may miss large insertion or 
deletion.15 Other methods include protein truncation 
testing (PTT), which detects abnormal shortened APC 
SURWHLQV DQGPXOWLSOH[ OLJDWLRQSUREH DPSOL¿FDWLRQ
that can detect large deletions and insertions. Mutations 
are detectable in nearly 85% of FAP patients, but only 
20-30% in AFAP patients.15 
There is a slight dilemma, however, to do 
genetic testing by some of hereditary CRC relatives. 
Psychological studies have found that even though 
genetic counseling enhance the accuracy of risk 
perception in hereditary cancer patients and their 
UHODWLYHV¿QGLQJVDOVRVXJJHVWWKDWJHQHWLFWHVWLQJPD\
cause little psychological distress.26 A study by Keogh 
HW DO WRZDUGV  UHODWLYHV RI FRQ¿UPHG/6SDWLHQWV
who declined offers of genetic testing showed that 
many patients believed that the test would not change 
their habits, including their regular checkups and their 
lifestyles.26 Others are not comfortable knowing the truth 
would impede them from getting health insurance policy.
CONCLUSION
As the incidence of the sporadic and hereditary 
colorectal cancer rises along with its mortality rate, 
people should be more aware on reducing their risk 
of having the disease by improving their way of life. 
Countries worldwide should support national screening 
programs for colorectal cancers, as well as genetic 
testing for possible carriers. Essentially, a challenging 
task for clinician is to educate hereditary CRC patients 
and their relatives to do early detection and prompt 
treatment of the cancer as patients with lynch syndrome 
and familial adenomatous Polyposis are susceptible 
not only to CRC but also cancer in other organs as 
well and screening tools have been proven to reduce 
mortality rate of CRC patients. Still, genetic counseling 
and psychological support from medical personnel are 
likewise much needed as a way to help improving their 
quality of life.
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